Venture Kick
VC Fund
Schlieren, Switzerland
Venture Kick is a VC fund in Schlieren focused on Health Care and Biotechnology. Venture Kick, a private philanthropic initiative, provides as much 150,000 Swiss francs in pre-seed funding to Swiss startups and offers structured, entrepreneurial training to build robust, winning businesses. Entrepreneurs pitch for finance as many as three times, as they compete for increasing amounts of funding at each stage. Founders gaindirect feedback from the expert juries and access to an international network of successful entrepreneurs and investors.Venture Kick has supported 600 Swiss startup projects with 24.9 million francs to date. Supported projects have incorporated as 454 active companies, creating 6,033 jobs, and attracting 2.49 billion francs worth of subsequent investment. Companies founded by Venture Kick alums represented 55 percent of the TOP 100 Swiss Startup Award 2018. In 2019 Venture Kick will support idea-stage startup projects with 4.35 million francs, to bring Swiss science to global markets.
- Total investments:
- 393
- Last investment:
- Lead investor:
- 72%
Last updated:
For AI agents: llms.txt
Industries Venture Kick invests in
Stages Venture Kick invests in
Countries Venture Kick invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Jordi Montserrat
|
|||
Mark Forster
|
|||
Investment Focus
Industry
- Health Care 55 (14%)
- Biotechnology 49 (12%)
- Medical 42 (11%)
- Artificial Intelligence 40 (10%)
- Manufacturing 36 (9%)
Stage
- Grant 238 (61%)
- Pre-Seed 46 (12%)
- Seed 35 (9%)
- Convertible Note 22 (6%)
- Debt Financing 1 (0%)
Country
- Switzerland 286 (73%)
- United States 4 (1%)
- France 1 (0%)
- Czech Republic 1 (0%)
- United Kingdom 1 (0%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Beat Schillig
Co-Managing Director
|
Co-Managing Director | Total investments: 3 | Find email | |
|
Jordi Montserrat
Founder
|
Founder | Total investments: 1 | Find email | |
|
Mark Forster
Jury Member
|
Jury Member | Total investments: 0 | Find email | |
Pascale Vonmont
Founder
|
Founder | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Immitra Bio
|
At Immitra Bio, we are developing a unique genetic medicine platform that combines two of the most powerful biomedical technologies: hematopoietic stem cells (HSCs) and CRISPR-Cas9 gene editing. Our novel technique allows for precise and long-lasting gene alterations within blood stem cells, resulting in transformational treatments for uncommondiseases with significant unmet medical needs. | $2.8M / Pre-Seed / Jul 21, 2026 | |
GoNeon
|
GoNeon employs agentic AI to create regulatory-compliant infrastructure and mobility strategies in minutes rather than months. | $185.2K / Grant / Jul 20, 2026 | |
RAROG
|
RAROG is an engineering company that converts common devices into rescue beacons that enable rescue teams to find lost individuals even in areas without mobile coverage. | $184.7K / Grant / Jul 14, 2026 | |
LaxiPed
|
LaxiPed is a manufacturer and supplier of foot arthrometer. | $49.4K / Grant / Jul 14, 2026 | |
Rhonexum
|
Rhonexum provides state-of-the-art low-temperature testing and modeling solutions for electronic components. | $185.5K / Grant / Jul 08, 2026 | |
ALP Bio
|
Alp Bio’s platform integrates tonsil organoid technology with advanced protein AI to identify and mitigate immunogenic risks in therapeutic antibodies, ensuring safer patient outcomes. | $186.8K / Grant / Jul 03, 2026 | |
Minysa
|
Minysa makes GaN semiconductor drivers for smaller, efficient aerospace & industrial electronics. | $186.3K / Grant / Jun 18, 2026 | |
|
Immitra Bio
|
At Immitra Bio, we are developing a unique genetic medicine platform that combines two of the most powerful biomedical technologies: hematopoietic stem cells (HSCs) and CRISPR-Cas9 gene editing. Our novel technique allows for precise and long-lasting gene alterations within blood stem cells, resulting in transformational treatments for uncommondiseases with significant unmet medical needs. | $189.1K / Grant / Jun 15, 2026 | |
Calmea
|
Calmea develops advanced contactless sensing systems that invisibly track sleep and automatically modify environment for perfect nightly rest | $188.1K / Grant / Jun 08, 2026 | |
Hephaistos
|
Hephaistos develops AI-based systems to design new enzymes from scratch for use in chemical and industrial reactions. The company applies machine-learning models to structural and sequence data to propose enzyme candidates with suitable activity, selectivity, and stability. Their workflow combines molecular modeling, structure prediction, andin-silico screening to prioritize variants before laboratory testing. The technology supports applications in biocatalysis and sustainable chemical production, where custom enzymes can replace conventional reaction methods. Hephaistos builds computational pipelines that help teams explore many design options and select enzymes that meet performance and manufacturability requirements. | $187.6K / Grant / Jun 01, 2026 | |
| See all 393 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Venture Kick invest in?
Venture Kick invests primarily in Health Care, Biotechnology and Medical startups, most often at Grant and Pre-Seed stage. Most of the 393 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Venture Kick?
Public channels for Venture Kick include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Venture Kick?
The team at Venture Kick includes Beat Schillig (Co-Managing Director), Jordi Montserrat (Founder) and Mark Forster (Jury Member). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
